Lilly’s Mounjaro as Effective on Heart Risks as Older Drug

A trial of Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro fell short of expectations that it would do a better job of preventing heart attacks and strokes than its older medicine Trulicity.

A head-to-head study of the two treatments — Lilly’s largest and longest of Mounjaro to date — was designed to prove what’s called non-inferiority, that Mounjaro was an acceptable alternative when it comes to reducing risks from major cardiovascular events compared with Trulicity.